We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Rystiggo UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
Product name
Rystiggo
Accepted date
Nov-2023
Active ingredients
rozanolixizumab
Proposed indication
For the treatment of generalised myasthenia gravis (gMG).
Application type
A (new medicine)
Publication date
Nov-2023